Future in-depth research employing gene-editing technologies, animal models, and clinical sample analyses will be essential to elucidate these mechanisms and to assess the potential of PPP2R1A as an independent prognostic biomarker or therapeutic target, thereby providing new directions for the clinical treatment of GC. This evidence concerns the gene PPP2R1A and gastric cancer.